Skip to main content

Povidone-iodine pharmacokinetics and study design

  • The original article was published in BMC Ophthalmology 2019 19:62
  • The Correspondence to this article has been published in BMC Ophthalmology 2020 20:328

Abstract

Dr. Gnanasekaran et al. reported the bactericidal activity of various concentrations of povidone iodine (PI) solution in an agar plate experiment of respiratory flora. The study design and the pharmacokinetic properties of PI solution ensured that dilute PI would not be effective in this study. These results may not replicate the typical clinical situation and are significantly different than a previously reported agar plate experiment, again owing to subtle but very significant differences in methodology.

Peer Review reports

Main text

We read with interest the study by Gnanasekaran et al., and would like to further discuss its methods and a similar agar plate in vitro study conducted by Silas et al. Gnanasekaran and colleagues exposed blood-agar plates to various concentrations of povidone iodine (PI), decanted excess fluid, waited 30 s and then loaded the plates with respiratory flora [1]. This is very different from loading the plates with bacteria and then applying PI solution.

Silas et al. found that by applying PI to blood agar plates already loaded with bacteria, 10, 5 and 2.5% PI eradicated all bacteria [2]. Applying 1% PI three times separated by 2 min produced similar results to 5% PI applied once. The differences between these two agar plate studies are the result of the timing of PI application; before or after the bacteria are loaded onto the plate. They also illustrate a contrast with liquid media-based studies, in which dilute PI solution can eradicate high concentrations of virulent bacteria in 15–30 s [3].

The pharmacokinetic properties of PI solution explain these findings; specifically, the reduction of bactericidal free iodine to iodide species after interaction with organic substances. Dilute PI solution has less total available iodine and therefore becomes “spent” or depleted earlier than more concentrated solutions [4].

Bearing this in mind, therefore, it is not surprising that the 1% PI solution did not inhibit bacterial growth at all; its limited free iodine was exhausted well before the lengthy bacterial loading process was complete. The conclusion “ophthalmologists should avoid diluting PI to concentrations lower than 5% for pre-injection antisepsis” is supported by this article only if usual practice consists of applying PI and then contaminating the site for 5 min. In contrast, if the eye is considered “dirty” prior to antisepsis, PI solution applied, and then the site kept clean for 30 s prior to injection, the results of this study are not applicable. In fact, 1% PI solution applied several times prior to injection can produce excellent antisepsis as shown by Silas et al.

Unfortunately, there is no standardized reliable way to simulate the ocular surface to better study this and related topics in vitro. Applying PI solution after bacteria are loaded onto the plates and waiting 30 sec for the solution to work could better simulate the situation in clinic, especially if typical precautions such as not talking and mask wearing are taken.

Availability of data and materials

Not applicable.

Abbreviations

PI:

Povidone iodine

References

  1. 1.

    Gnanasekaran S, Rogers S, Wickremasinghe S, Sandhu SS. The effect of diluting povidone-iodine on bacterial growth associated with speech. BMC Ophthalmol. 2019;19(1):62.

    PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Silas MR, Schroeder RM, Thomson RB, Myers WG. Optimizing the antisepsis protocol: effectiveness of 3 povidone-iodine 1.0% applications versus a single application of povidone-iodine 5.0. J Cataract Refract Surg. 2017;43(3):400–4.

    PubMed  Article  Google Scholar 

  3. 3.

    Koerner JC, George MJ, Kissam EA, Rosco MG. Povidone-iodine concentration and in vitro killing time of bacterial corneal ulcer isolates. Digit J Ophthalmol. 2018;24(4):24–6 Povidone-iodine concentration and in vitro killing time of bacterial corneal ulcer isolates.

    PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Grzybowski A, Kanclerz P, Myers WG. The use of povidone-iodine in ophthalmology. Curr Opin Ophthalmol. 2018;29(1):19–32.

    PubMed  Article  Google Scholar 

Download references

Acknowledgements

None.

Funding

Not applicable.

Author information

Affiliations

Authors

Contributions

Both authors read and approved the final manuscript.

Authors’ information

JK is interested in research to prevent post procedure infection in ophthalmology by improving our understanding and awareness of non-antibiotic antimicrobial agents.

Corresponding author

Correspondence to Jagger Koerner.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Koerner, J., Grzybowski, A. Povidone-iodine pharmacokinetics and study design. BMC Ophthalmol 20, 29 (2020). https://doi.org/10.1186/s12886-020-1313-9

Download citation

Keywords

  • Endophthalmitis prophylaxis
  • Povidone-iodine
  • Intravitreal injection